Any antineoplastic agent (standard or investigational) within 2 weeks prior to starting trial treatment

Radiosurgery or radiotherapy for target lesions within 2 weeks prior to starting trial treatment

Prophylactic use of hematopoietic growth factors within 1 week prior to starting trial treatment

Active Central Nervous System (CNS) metastases or carcinomatous meningitis

Women who are pregnant

Women who are breastfeeding

Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer